Discharge Plan

XII.
DISCHARGE PLAN
M-Medications to continue at home

NAME
OF MEDICINE
1. Cefuroxime
2. NeoPenotran
3. Maalox
4. Sangobian
PURPOSE
AMOUNT/DOSE
Treatment of susceptible infections which

include bone and joint infections,
bronchitis (and other lower respiratory
tract infections), gonorrhea, meningitis
(although treatment failures have been
reported in H. influenzae meningitis), otitis
media, peritonitis, pharyngitis, sinusitis,
skin infections (including soft tissue
infections) and urinary tract infections.
Injection: Prophylaxis for surgical infection.
500mg/tab
FREQUENCY/ROUTE/
DURATION
PO/ BID X 7days
Treatment of vaginal candidiasis caused

by Candida albicans, bacterial vaginitis
caused by anaerobic bacteria
and Gardnerella vaginalis, trichomonal
vaginitis caused by Trichomonas
vaginalis and mixed vaginal infections.
-Symptomatic relief to upset stomach
associated hyperacidity
-Hyperacidity associated with peptic ulcer,
gastritis, peptic esophagatis, gastric hyper
acidity, and hiatal hernia
-Short-term relief of constipation,
evacuation of the colon for rectal
andbowel examination
-Cap: Fe-deficiency anemia & anemia
during growth, old age & convalescence;
megaloblastic anemia during pregnancy,
in sprue or parasitosis; anemia due to
100mg/suppository
Suppository x 3 days
1 tab
1 hr post meal & bedtime
1 cap
QD
5. Prednisome
6. Aspilet
general dietary insufficiency; anemia

prophylaxis in blood donors. Prevention of
maternal constipation due to pregnancy &
Fe intolerability. Syr: Fe-deficiency anemia
in childn, latent insufficiency of Fe & vit B;
in chronic illnesses & during
convalescence. Drops: Fe & folic acid
supplement for anemia during growth
period.
-Replacement o therapy in adrenal cortical
sufficiency
-Hypercalcemia associate with cancer
-Short-term management of various
inflammatory and allergic disorders, such
as rheumatoid arthritis, collagen disease,
dermatologic disease, status asthmaticus
and autoimmune disorders.
Mild to moderate pain
Fever
Inflammatory conditions- rheumatic fever,
rheumatoid arthritis, osteoarthritis,
juvenile rheumatoid arthritis,
spondyloarthropathies
Reduction of risk of recurrent TIAs or
stroke in patients with history of TIA due to
fibrin platelet emboli or ischemic stroke
Reduction of risk of death or nonfatal MI in
patients with history of infarction or
unstable angina pectoris or suspected
acute MI
Patients who have undergone
revascularization procedures
Unlabeled uses: Prophylaxis against
cataract formation with long-term use;
prosthetic valve thromboprophylaxis,
10mg/tab
1 tab QD
80mg/tab
1 tab QD
Kawasaki disease, antithrombotic therapy

in children with Blalock-Taussig shunt an
after Fontan procedure
E-Exercises
Not applicable; strictly for bedrest
T-Treatment
For urinalysis after 7 days intake of Cefuroxime
H-Health Teaching
Title: Health teaching about prevention and treatment of urinary tract infection
Learning Objectives
Learning content
After the discussion, the

client will be able to know
how to prevent and treat
urinary tract infection.
The
discussion
will
include the following:
Definition of UTI
Signs
and
symptoms
Causes of UTI
Complications of
UTI
Tests
and
diagnosis.
Treatment of UTI.
Prevention of UTI.
Time
allotment
The discussion
will last for
25-30
minutes.
Strategy/
Methodology
Assess
the
current
knowledge of the
client
about
urinary
tract
infections
Give the client a
brochure
or
handout
containing all the
information that
will be discussed.
Encourage active
Resources
http://www.mayocli
nic.org/diseasesconditions/urinarytractinfection/basics/de
finition/con20037892
Evaluation
participation
of
the
client
by
asking questions
during
the
discussion.
Comment/s:
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
_____________________________
O-Out Patient
DOCTORS
NAME
Dr. Vega
Dr. Baes
DATE
TIME
After 1 week
Once with Urinalysis
result
D-Diet
Diet as tolerated then Non per orem if with hypogastric pain
S-Sexuality/Spirituality
Abstinence in sexual intercourse
CLINICS
LOCATION
FEU-NRMF
FEU-NRMF
CLINICS TEL. NO.

427-0213
427-0213

Discharge Plan

Uploaded by

Copyright:

Available Formats

Discharge Plan

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Discharge Plan

Uploaded by

Copyright:

Available Formats

What medications is the patient prescribed?

What health teaching will the patient receive?

XII.

M-Medications to continue at home

Treatment of susceptible infections which

Treatment of vaginal candidiasis caused

1 hr post meal & bedtime

general dietary insufficiency; anemia

Kawasaki disease, antithrombotic therapy

Not applicable; strictly for bedrest

For urinalysis after 7 days intake of Cefuroxime

After the discussion, the

Diet as tolerated then Non per orem if with hypogastric pain

Abstinence in sexual intercourse

CLINICS TEL. NO.

You might also like